Masteron vs Testosterone
Moderate Research vs FDA Approved
synergistic Researched · 95% Testosterone is the standard base compound run alongside Masteron. Masteron complements testosterone by providing anti-estrogenic activity that can reduce or eliminate the need for a dedicated AI, while testosterone provides the anabolic foundation and maintains normal physiological function. A common ratio is equal doses or slightly higher testosterone. Masteron enhances the aesthetic quality of a testosterone cycle by reducing water retention and promoting a harder appearance.
Molecular Data
Masteron Testosterone
Weight 304.47 Da (base) 288.42 Da (base)
Half-life ~2 days (propionate), ~10 days (enanthate) ~8 days (cypionate)
Type DHT-derived anabolic steroid (C20H32O2) Steroid hormone (C19H28O2)
Key Benefits
Masteron
01 Produces a hard, dry, and grainy appearance by eliminating subcutaneous water retention
02 Mild anti-estrogenic properties that can reduce or replace the need for aromatase inhibitors on cycle
03 Does not aromatize, eliminating estrogen-mediated side effects from the compound itself
04 Enhances the visual effects of other steroids in a stack by reducing water retention and bloat
05 Modest increases in strength without significant weight gain, useful for weight-class athletes
06 Improves muscle density and vascularity at low body fat percentages
07 Well-tolerated with a relatively mild side effect profile compared to other anabolic steroids
08 Short detection window with propionate ester compared to many other injectable steroids
Testosterone
01 Restoration of normal testosterone levels in hypogonadal men
02 Increased lean muscle mass and strength
03 Improved bone mineral density and reduced fracture risk
04 Enhanced libido, sexual function, and erectile quality
05 Improved mood, energy, motivation, and cognitive clarity
06 Reduction in body fat percentage, particularly visceral fat
07 Increased red blood cell production and oxygen-carrying capacity
08 Improved insulin sensitivity and metabolic health markers
Dosing Protocols
Masteron
300-500 mg/week / Every other day (propionate) or 2x per week (enanthate)
Cutting / Aesthetic Enhancement 300-400 mg/week Every other day (propionate) or 2x per week (enanthate)
Contest Preparation 400-500 mg/week Every other day or daily (propionate)
AI Replacement / Estrogen Management 200-300 mg/week Every other day (propionate) or 2x per week (enanthate)
Testosterone
100-200 mg/week (TRT) / 1-2x per week (injectable)
TRT - Standard Replacement 100-200 mg/week 1-2x per week
TRT - Conservative Start 80-100 mg/week 2x per week (40-50 mg per injection)
TRT - Propionate Protocol 25-50 mg every other day Every other day or 3x per week
Performance Enhancement - Moderate 300-500 mg/week 2x per week
Performance Enhancement - Advanced 500-750 mg/week 2-3x per week
Side Effects
Masteron
Hair loss and accelerated male pattern baldness (significant risk as a DHT derivative - the most commonly reported side effect)
Acne and increased skin oiliness, particularly on the back and shoulders
Suppression of natural testosterone production (requires PCT or ongoing TRT)
Injection site pain or discomfort (more common with propionate ester)
Mild aggression or irritability from elevated androgenic activity
HDL cholesterol suppression and adverse lipid profile changes
Testosterone
Acne and oily skin (increased sebum production via DHT)
Water retention and bloating (estrogen-mediated)
Mild mood changes (irritability, increased assertiveness)
Increased hematocrit and hemoglobin (erythrocytosis)
Testicular atrophy (suppression of LH/FSH from exogenous testosterone)
Injection site pain, redness, or irritation
Increased body hair growth
Mild elevation in blood pressure
Contraindications
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Pregnancy or potential for pregnancy (causes virilization of female fetus)
Known hypersensitivity to drostanolone or any formulation components
Severe hepatic impairment
Pre-existing significant hair loss where further androgenic exposure is unacceptable
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled cardiovascular disease or severe dyslipidemia
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled severe heart failure
Untreated severe obstructive sleep apnea
Desire for near-term fertility (without concurrent HCG/FSH)
Pregnancy or potential exposure to pregnant women (Category X)
Hypersensitivity to testosterone or any formulation components
Research Evidence
Masteron Testosterone
Status Moderate Research FDA Approved
References 5 studies 5 studies
Latest March 2020 June 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.